Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension
NCT ID: NCT02211352
Last Updated: 2014-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
58 participants
INTERVENTIONAL
2012-05-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation
NCT00730951
Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation
NCT00728221
Effect of Ginseol Kg1 on Blood Pressure Lowering
NCT01483430
Effect of Korean Red Ginseng Extract on Blood Flow in Healthy Adults
NCT06236243
Stress Relief Effect of Korean Red Ginseng
NCT01542905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants were not allowed to change their antihypertensive medications except safety issue. Brachial systolic BP (SBP), diastolic BP (DBP), Central SBP and DBP will measured at baseline,at 2 and 4 months.
Efficacy and safety data will be monitored by Daegu Catholic University Medical Center Institutional Review Board and reported to the Korean Ginseng Society.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active(Korean Red Ginseng) first group:
Korean Red Ginseng Capsules 2g,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Korean Red Ginseng Capsules
Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Placebo capsules
placebo Capsules(2g),daily, 8 week and than crossover to Korean Red Ginseng capsules(2g), daily 8week
Placebo
Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Korean Red Ginseng Capsules
Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Placebo
Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diastolic blood pressure 100 mmHg or less and systolic blood pressure 160 mmHg or less
Exclusion Criteria
* Serum creatinin above 1.5 mg/dL
* aspartate aminotransferase(AST) and alanine aminotransferaseALT above two times upper normal limits
* Uncontrolled diabetes (Hb A1c \< 9%)
* Acute myocardial infarction or coronary artery disease intervention within six months
* Moderate to severe congestive heart failure
* HIV positive
* Immunocompromized host
* Allergy to Korean red ginseng
* Pregnancy or plan to pregnancy
* Alcohol or drug abuse
* Attend to other clinical trial within 12 weeks
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Korean Society of Ginseng
OTHER
Daegu Catholic University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jin Bae Lee
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jin Bae Lee, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Daegu Catholic University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Daegu Catholic University Medical Center
Daegu, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GS302-100
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
GS302-100
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.